NY-ESO-1 Vaccine Trial to be Available in Missouri

General Blog
1

Adaptimmune, the company that provides the T cell receptor for the NIH vaccine trial just announced that they plan to open the same trial later this year at Washington University, St Louis, in Missouri.

Here is the announcement:

http://www.bioportfolio.com/news/article/751272/Adaptimmune-Announces-Opening-Of-Pilot-Clinical-Trial-In-Synovial-Sarcoma-Personalized-Therapy.html

And here is the information about the clinical trial, with contact numbers:

http://clinicaltrials.gov/ct2/show/NCT01343043